Best Clinical Practice of Management of Side Effects of Bpal Regimen (Clinical Case)

Abstract

New 6-months regimen based on bedaquiline, pretomanid and linesolid (BPaL), evaluated in TB-PRACTECAL clinical trial, is one of modern treatments for extensively drug resistant tuberculosis. Patients on BPaL should be carefully observed for side effects, especially liver toxicity, myelosuppression, peripheral and optic neuropathy, QT-interval prolongation and pancreatitis. A clinical case of extensively drug resistant tuberculosis with the outcomes of BPaL regimen treatment on the backgrounds of side effects is presented in current report. This case demonstrates that timely and thorough monitoring of side effects allows to preserve the BPaL regimen modality, regardless the occurrence of several adverse effects in one person and to complete the prescribed course of treatment, which resulted in cure. Key words: extensively drug resistant tuberculosis, BPaL regimen of treatment, saide effects.

Evaluation of the effectiveness of bedaquiline and delamanid treatment among children and adolescents with multi-drug-resistant pulmonary tuberculosis

“…Ukraine is one out of ten countries with the highest burden of multidrug-resistant pulmonary and extrapulmonary tuberculosis (MDR-TB) [15,16,19]. On the background of positive dynamics of the reduction of mortality and incidence of new cases of TB the situation with MDR-TB has been DPELJXRXV LQ UHFHQW \HDUV ,Q 8NUDLQH VFLHQWL˝F works carried out by V.M.…”

“…7KHUH LV D VLJQL˝FDQW GHFUHDVH LQ WKH H˜HFWLYHQHVV RI WKH WUHDWPHQW DPRQJ WKH SDWLHQWV in Ukraine and in the world on the background of 0'57% DQG ;'57% >@ 7KH LQVX˟FLHQW H˜HFWLYHQHVV RI FKHPRWKHUDS\ UHJLPHQV &75V which were based on traditional antimycobacterial drugs (AMDs) second-line, and the accumulation of the evidence base regarding new AMDs became a factor in improving existing treatment and forming regimens with the use of new AMDs, such as bedaquiline (Bdq), delamanid (Dlm) and pretomanid (Pa) both among adults, children and adolescents [1,3,7,10,14,15,17,18,[20][21][22][23][24].…”